Saudi-Arabien - Englisch - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

astrazeneca ag, switzerland - candesartan cilexetil,hydrochlorothiazide - tablet - 16,12.5 mg,

Saudi-Arabien - Englisch - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

astrazeneca ag, switzerland - candesartan cilexetil - tablet - 4 mg

Saudi-Arabien - Englisch - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

astrazeneca ag, switzerland - candesartan cilexetil - tablet - 8 mg

Saudi-Arabien - Englisch - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

astrazeneca ag, switzerland - candesartan cilexetil - tablet - 16 mg

Saudi-Arabien - Englisch - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

astrazeneca ag, switzerland - candesartan cilexetil - tablet - 32 mg

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.25mg; terbutaline sulfate 200ug equivalent to 0.25 mg metered dose - powder for inhalation - 0.25 mg/dose - active: terbutaline sulfate 0.25mg terbutaline sulfate 200ug equivalent to 0.25 mg metered dose excipient: lactose monohydrate - relief of bronchospasm occurring in bronchial asthma, bronchitis and other bronchopulmonary conditions where bronchospasm is a complicating factor. acute prophylaxis in situations known to induce bronchospasm, e.g. exercise induced asthma.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.5mg - powder for inhalation - 0.5 mg/dose - active: terbutaline sulfate 0.5mg

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - bicalutamide 150mg - film coated tablet - 150 mg - active: bicalutamide 150mg excipient: hypromellose lactose monohydrate macrogol 300 magnesium stearate povidone purified water   sodium starch glycolate titanium dioxide

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - fulvestrant 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml   excipient: benzyl alcohol benzyl benzoate castor oil ethanol - faslodex is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: - not previously treated with endocrine therapy, or - previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;  ; bicalutamide 50mg - combination - 10.8mg+50mg pack - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.